TEV Overzicht aandelen Teva Pharmaceutical Industries Limited ontwikkelt, produceert, verkoopt en distribueert generieke geneesmiddelen, speciale geneesmiddelen en biofarmaceutische producten in Noord-Amerika, Europa, Israël en internationaal. Meer informatie
Beloningen Risicoanalyse Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
Teva Pharmaceutical Industries Limited Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Teva Pharmaceutical Industries Historische aandelenkoersen Huidige aandelenkoers US$21.00 52 Week Hoogtepunt US$21.50 52 Week Laag US$9.16 Bèta 0.80 1 maand verandering 35.05% 3 maanden verandering 34.19% 1 Jaar Verandering 127.77% 3 jaar verandering 183.02% 5 jaar verandering 147.93% Verandering sinds IPO -25.90%
Recent nieuws en updates
Teva Pharmaceutical Industries Limited to Report Q4, 2024 Results on Jan 29, 2025 Dec 21
Third quarter 2024 earnings released: US$0.39 loss per share (vs US$0.071 profit in 3Q 2023) Nov 08
Teva Pharmaceuticals Limited Unveils New Phase 3 Positive Results for Olanzapine Lai, and Presents Real-World Data on Uzedy At Psych Congress 2024 Nov 04
Alvotech and Teva Pharmaceutical Industries Ltd. Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn) Oct 22
Teva Pharmaceutical Industries Limited to Report Q3, 2024 Results on Nov 06, 2024 Oct 01
Second quarter 2024 earnings released: US$0.75 loss per share (vs US$0.77 loss in 2Q 2023) Aug 01 Meer updates bekijken
Teva Pharmaceutical Industries Limited to Report Q4, 2024 Results on Jan 29, 2025 Dec 21
Third quarter 2024 earnings released: US$0.39 loss per share (vs US$0.071 profit in 3Q 2023) Nov 08
Teva Pharmaceuticals Limited Unveils New Phase 3 Positive Results for Olanzapine Lai, and Presents Real-World Data on Uzedy At Psych Congress 2024 Nov 04
Alvotech and Teva Pharmaceutical Industries Ltd. Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn) Oct 22
Teva Pharmaceutical Industries Limited to Report Q3, 2024 Results on Nov 06, 2024 Oct 01
Second quarter 2024 earnings released: US$0.75 loss per share (vs US$0.77 loss in 2Q 2023) Aug 01 Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease Jul 25
Teva Pharmaceutical Industries Limited Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY (fremanezumab) Space Trial for Prevention of Episodic Migraine Jul 18
Teva Pharmaceutical Industries Limited to Report Q2, 2024 Results on Jul 31, 2024 Jul 04
Teva Pharmaceutical Industries Ltd Announces New AJOVY® (Fremanezumab) Migraine Prevention Data Challenges Treatment Pauses Jun 29
Teva Pharmaceutical Industries Limited Announces Launch of Authorized Generic of Victoza® (Liraglutide Injection 1.8Mg), in the United States Jun 25
Teva Pharmaceutical Industries Limited Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day) May 30
Teva Pharmaceutical Industries Limited Announces Management Changes, Effective June 3, 2024 May 16 Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2024
First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.18 loss in 1Q 2023) May 09 Teva Pharmaceutical Industries Limited, Annual General Meeting, Jun 06, 2024
Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China Apr 11
Teva Pharmaceutical Industries Limited to Report Q1, 2024 Results on May 08, 2024 Apr 10
Full year 2023 earnings released: US$0.50 loss per share (vs US$2.12 loss in FY 2022) Feb 01
Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023 Feb 01
Teva Pharmaceutical Industries Limited Announces Earnings Guidance for Full Year 2024 Jan 31
Court for the District of New Jersey Issues A Decision That Teva Pharmaceuticals Does Not Infringe Any Asserted Claims of Corcept Therapeutics Incorporated’s U.S. Patents Jan 02
Teva Pharmaceutical Industries Limited Announces Post Hoc Phase 3 Data Analysis Shows AJOVY (Fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-Morbid Obesity Dec 06
Third quarter 2023 earnings released: EPS: US$0.071 (vs US$0.05 in 3Q 2022) Nov 10
Teva Pharmaceutical Industries Ltd. Appoints R. Ananthanarayanan (Ananth) as CEO of Its Teva Active Pharmaceutical Ingredients Business Nov 08
Teva Pharmaceutical Industries Limited Announces Phase IV Unite Study Shows Ajovy® (Fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder Oct 17
Teva Pharmaceutical Industries Limited to Report Q3, 2023 Results on Nov 08, 2023 Oct 07
Teva Announces Changes to Executive Management Team Sep 29
Teva Pharmaceutical Industries Limited Appoints Varda Shalev as Member of the Board, Effective September 1, 2023 Aug 05 Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Second Quarter Ended June 30, 2023
Second quarter 2023 earnings released: US$0.77 loss per share (vs US$0.21 loss in 2Q 2022) Aug 04
Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development, Effective August 1, 2023 Jul 28
New minor risk - Share price stability Jul 09 Teva Pharmaceutical Industries Limited to Report Q2, 2023 Results on Aug 02, 2023
Teva Pharmaceutical Industries Ltd. Announces Further Positive Data from the Pan-European Research Study Jul 01
Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY Jun 17 Teva Pharmaceuticals Presents Real-World Data for Austedo (Deutetrabenazine) Tablets with 4-Week Patient Titration Kit At Psych Congress Elevate 2023 Jun 03
Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting May 21
Teva Pharmaceutical Industries Limited Announces That Once-Daily Austedoxr (Deutetrabenazine) Extended-Release Tablets Are Now Available for Adults in the United States May 16
Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2023 May 11
First quarter 2023 earnings released: US$0.19 loss per share (vs US$0.86 loss in 1Q 2022) May 11
Full year 2022 earnings released: US$2.12 loss per share (vs US$0.38 profit in FY 2021) Feb 09
Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2023 Feb 09
Teva Pharmaceutical Industries Limited to Report Q4, 2022 Results on Feb 08, 2023 Jan 13
Karo Pharma AB (publ) agreed to acquire of Six brands of Teva for DKK 84 million. Dec 06 Teva Pharmaceutical Industries Limited Appoints Richard Francis as President, Effective January 1, 2023
Third quarter 2022 earnings released: EPS: US$0.05 (vs US$0.27 in 3Q 2021) Nov 05 Teva Pharmaceutical Industries Limited Revises Earnings Guidance for the Year 2022
Teva Pharmaceutical Industries Limited Reaches Agreement with Arkansas to Settle the State’s Price Fixing Claims Oct 08 Teva Pharmaceutical Industries Limited to Report Q3, 2022 Results on Nov 03, 2022 Teva Pharmaceutical Industries Limited Presents Studies of Effectiveness of AJOVY for Treatment of Migraine in Patients with Co-morbid Depression
Exelixis, Inc. Files Complaint in the United States District Court for the District of Delaware for Patent Infringement against Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc Sep 03
Teva Pharmaceutical Industries Limited Announces European Commission Grants Marketing Authorization for Ranivisio (Ranibizumab), for Age-Related Macular Degeneration (AMD) the Most Common Cause of Blindness in Developed Countries Aug 29
Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2022 Jul 29
Teva Pharmaceutical Industries Limited Announces Impairment Charges for the Second Quarter Ended June 30, 2022 Jul 28
Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.19 profit in 2Q 2021) Jul 27
Teva Pharmaceutical Industries Limited Appoints Eric A. Hughes as Executive Vice President, Global R&D and Chief Medical Officer Jul 02
Teva Pharmaceutical Industries Limited to Report Q2, 2022 Results on Jul 27, 2022 Jun 30 Teva Pharmaceutical Industries Limited Welcomes the UK Medicines & Healthcare Regulatory Agency Decision to Grant A Licence for Ongavia May 18
Teva Pharmaceutical Industries Limited Revises Earnings Guidance for the Full Year 2022
First quarter 2022 earnings released: US$0.86 loss per share (vs US$0.07 profit in 1Q 2021) May 04
Teva Pharmaceutical Industries Limited to Report Q1, 2022 Results on May 03, 2022 Apr 05
Investor sentiment improved over the past week Mar 31
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 10
Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2022 Feb 10
Teva Announces Launch of First-To-Market Generic Version of Narcan (Naloxone Hydrochloride Nasal Spray), in the U.S Dec 23
Chief Accounting Officer Andrew Weil has left the company Dec 01
Third quarter 2021 earnings released: EPS US$0.27 (vs US$3.97 loss in 3Q 2020) Oct 28
Teva Pharmaceutical Industries Limited Reaches Agreement with Louisiana to Settle the State’s Opioid-Related Claims Oct 01
Forecast to breakeven in 2021 Sep 23
Executive Vice President of North America Commercial Brendan O'Grady has left the company Aug 18
Executive Vice President of North America Commercial Brendan O'Grady has left the company Aug 18
Insufficient new directors Aug 01
Second quarter 2021 earnings released: EPS US$0.19 (vs US$0.13 in 2Q 2020) Jul 30
Independent Director Abbas Hussain has left the company Jul 15
Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults Jun 24
Teva Announces Its Launch of the First Generic Perforomist®, Formoterol Fumarate Inhalation Solution, 20 mcg/2 ML, Used to Treat Chronic Obstructive Pulmonary Disease (COPD), in the United States Jun 23 Teva Pharmaceutical Industries Ltd. Presents Analysis on AJOVY® (fremanezumab) Injection
Executive Vice President of International Markets Commercial Gianfranco Nazzi has left the company May 01
Teva Pharmaceutical Industries Limited Announces the Launch of the First Generic Version of Absorica (Isotretinoin) Capsules, for the Treatment of Severe Recalcitrant Nodular Acne in Patients 12 Years of Age and Older, in the United States Apr 30
First quarter 2021 earnings released: EPS US$0.07 (vs US$0.063 in 1Q 2020) Apr 30
Teva Pharmaceutical Industries Limited Reaffirms Its Earnings Guidance for the Year 2021 Apr 29
Teva to Present New Analyses of AUSTEDO (deutetrabenazine) Tablets and Assessment of Schizophrenia Clinical Outcomes at Upcoming 2021 American Psychiatric Association Annual Meeting Apr 28 Rendement voor aandeelhouders TEV DE Pharmaceuticals DE Markt 7D 2.4% -0.3% -0.3% 1Y 127.8% -17.0% 7.0%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: TEV overtrof de German Pharmaceuticals industrie, die het afgelopen jaar een rendement -17 % opleverde.
Rendement versus markt: TEV overtrof de German markt, die het afgelopen jaar een rendement opleverde van 7 %.
Prijsvolatiliteit Is TEV's price volatile compared to industry and market? TEV volatility TEV Average Weekly Movement 8.4% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stabiele aandelenkoers: De aandelenkoers van TEV is de afgelopen 3 maanden volatiel geweest.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van TEV is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen German.
Over het bedrijf Teva Pharmaceutical Industries Limited ontwikkelt, produceert, verkoopt en distribueert generieke geneesmiddelen, speciale geneesmiddelen en biofarmaceutische producten in Noord-Amerika, Europa, Israël en internationaal. Het biedt generieke geneesmiddelen in verschillende doseringsvormen, zoals tabletten, capsules, injecteerbare middelen, inhaleermiddelen, vloeistoffen, transdermale pleisters, zalven en crèmes; steriele producten, hormonen, hoogpotente geneesmiddelen en cytotoxische stoffen in parenterale en vaste doseringsvormen; en generieke producten met medische hulpmiddelen en combinatieproducten. Het bedrijf richt zich op het centrale zenuwstelsel (CZS), de luchtwegen en oncologie.
Meer tonen Teva Pharmaceutical Industries Limited Samenvatting Hoe verhouden de winst en inkomsten van Teva Pharmaceutical Industries zich tot de beurswaarde? TEV fundamentele statistieken Marktkapitalisatie €24.44b Inkomsten(TTM ) -€921.41m Inkomsten(TTM ) €16.11b
1.5x P/S-verhouding
-26.5x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) TEV resultatenrekening (TTM ) Inkomsten US$16.77b Kosten van inkomsten US$8.41b Brutowinst US$8.36b Overige uitgaven US$9.32b Inkomsten -US$959.00m
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
Jan 29, 2025
Winst per aandeel (EPS) -0.85 Brutomarge 49.84% Nettowinstmarge -5.72% Schuld/Eigen Vermogen Verhouding 297.3%
Hoe presteerde TEV op de lange termijn?
Bekijk historische prestaties en vergelijking
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2024/12/26 23:59 Aandelenkoers aan het einde van de dag 2024/12/23 00:00 Inkomsten 2024/09/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .
Bronnen van analisten Teva Pharmaceutical Industries Limited wordt gevolgd door 60 analisten. 9 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Jasper Hellweg Argus Research Company Richard Silver Barclays Balaji Prasad Barclays
Toon 57 meer analisten 
